The US FDA study is intended to evaluate the system for treating life-threatening ventricular tachyarrhythmias.

"Appropriately selected patients with NICM have the potential to benefit from primary prevention ICD therapy…Besides consideration of ICD placement, attention to guideline-directed medical therapy and ...

NEW ORLEANS, Nov. 9 – A small study of patients with heart failure not caused by blocked arteries indicates that women, as well as men, may benefit from implantable cardioverter-defibrillators (ICD) ...

Background: Because the natural history of atrial tachyarrhythmia (AT) is not known in patients with implantable cardioverter-defibrillators (ICDs) but without device-based atrial therapies, we aimed ...

Please provide your email address to receive an email when new articles are posted on . Researchers have developed a risk model to help predict the chances of adverse events after a patient receives ...

Placement of an implantable cardioverter-defibrillator (ICD) in patients with non-ischemic systolic heart failure did not improve overall survival compared to usual clinical care -- although a ...

The study was performed using data from 109 patients who were on DA-therapy at the time of device implantation. The control group consisted of 318 patients of which 104 patients (32.7%) were on ASA.

Improvements in optimal medical therapy for patients with heart failure with reduced ejection fraction (HFrEF) have helped reduce the risk of sudden cardiac death (SCD)—in the modern era, though, just ...

(HealthDay News) – A simple model may be used to predict risk for in-hospital adverse events among patients receiving an implantable cardioverter defibrillator (ICD), according to research published ...

Study finds no difference in all-cause mortality among patients with chronic kidney disease and heart failure who received implantable cardioverter defibrillators and those who did not. Research has ...